Besides, obvious trends towards inferior treatment outcomes and borderline confidence intervals were observed, the author speculated that KRAS mutation is still a valid predictor for poor treatment outcomes in EGFR wild-type NSCLC with more publications to be included. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.